Advertisement
Research ArticleArticle

Genotoxicity of 2-(3-Chlorobenzyloxy)-6-(piperazinyl)pyrazine, a Novel 5-Hydroxytryptamine2c Receptor Agonist for the Treatment of Obesity: Role of Metabolic Activation

Amit S. Kalgutkar, Deepak K. Dalvie, Jiri Aubrecht, Evan B. Smith, Stephanie L. Coffing, Jennifer R. Cheung, Chandra Vage, Mary E. Lame, Phoebe Chiang, Kim F. McClure, Tristan S. Maurer, Richard V. Coelho Jr., Victor F. Soliman and Klaas Schildknegt
Drug Metabolism and Disposition June 2007, 35 (6) 848-858; DOI: https://doi.org/10.1124/dmd.106.013649

Article Information

vol. 35 no. 6 848-858
DOI 
https://doi.org/10.1124/dmd.106.013649
PubMed 
17344339
Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received November 1, 2006
  • Accepted March 2, 2007
  • Published online May 18, 2007.

Article Versions

Copyright & Usage 
The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Amit S. Kalgutkar,
  2. Deepak K. Dalvie,
  3. Jiri Aubrecht,
  4. Evan B. Smith,
  5. Stephanie L. Coffing,
  6. Jennifer R. Cheung,
  7. Chandra Vage,
  8. Mary E. Lame,
  9. Phoebe Chiang,
  10. Kim F. McClure,
  11. Tristan S. Maurer,
  12. Richard V. Coelho, Jr.,
  13. Victor F. Soliman and
  14. Klaas Schildknegt
  1. Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Groton, Connecticut (A.S.K., C.V., M.E.L., T.S.M., V.F.S.) and La Jolla, California (D.K.D., E.B.S.); and Safety Sciences (J.A., S.L.C., J.R.C.), Cardiovascular and Metabolic Diseases Chemistry (P.C., K.F.M.), and Chemical Research and Development (K.S., R.V.C.), Pfizer Global Research and Development, Groton, Connecticut
  1. Address correspondence to:
    Dr. Amit S. Kalgutkar, Pharmacokinetics, Dynamics, and Metabolism Department, Pfizer Global Research and Development, Groton, CT 06340. E-mail: amit.kalgutkar{at}pfizer.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: August 2017 to August 2022

AbstractFullPdf
Aug 20171155
Sep 201732917
Oct 20173235
Nov 20172176
Dec 201722910
Jan 20184143
Feb 201832511
Mar 20181214
Apr 201813413
May 20180275
Jun 20181229
Jul 20184167
Aug 20180177
Sep 20180155
Oct 2018094
Nov 2018162
Dec 2018521
Jan 2019903
Feb 2019815
Mar 2019833
Apr 2019823
May 2019712
Jun 2019605
Jul 2019811
Aug 20191412
Oct 20192402
Nov 20191342
Dec 20191821
Jan 20202334
Feb 20202421
Mar 20201301
May 2020932
Jun 2020911
Jul 20201201
Aug 2020723
Sep 2020622
Oct 20201602
Nov 20201810
Dec 20201313
Jan 20211212
Feb 20211235
Mar 20211587
Apr 2021723
May 20211534
Jun 20212412
Jul 20212322
Aug 20211024
Sep 2021710
Oct 2021321
Nov 20211132
Dec 20212732
Jan 20221134
Feb 2022611
Mar 20221511
Apr 20221342
May 20221520
Jun 20222122
Jul 20222118
Aug 2022700

Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

Genotoxicity of 2-(3-Chlorobenzyloxy)-6-(piperazinyl)pyrazine, a Novel 5-Hydroxytryptamine2c Receptor Agonist for the Treatment of Obesity: Role of Metabolic Activation

Amit S. Kalgutkar, Deepak K. Dalvie, Jiri Aubrecht, Evan B. Smith, Stephanie L. Coffing, Jennifer R. Cheung, Chandra Vage, Mary E. Lame, Phoebe Chiang, Kim F. McClure, Tristan S. Maurer, Richard V. Coelho, Victor F. Soliman and Klaas Schildknegt
Drug Metabolism and Disposition June 1, 2007, 35 (6) 848-858; DOI: https://doi.org/10.1124/dmd.106.013649
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement